V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330013152 | 330004714 | 1.67 | null | Curative (C) | 2015-09-16 | 2015-09-16 | EURAMOS TRIAL | null | null | 330013156 | EURAMOS TRIAL |
| 330013153 | 330004739 | 0 | 35.4 | Palliative (P) | 2018-05-16 | 2018-05-24 | EURAMOS TRIAL | 2 | N | 330013247 | EURAMOS TRIAL |
| 330013154 | 330008592 | 1.62 | 65.3 | Palliative (P) | 2018-04-29 | 2018-05-20 | Cisplatin + Docetaxel +Fluorouracil | 2 | Y | 330013308 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 330013155 | 330004783 | 1.66 | null | Adjuvant (A) | 2019-09-25 | 2019-10-27 | VAI (Ifos 3g/m2) | N | N | 330013538 | VAI |
| 330013157 | 330004821 | 1.9 | 85.4 | Palliative (P) | 2017-08-22 | 2017-08-22 | Trabectedin | N | null | 330013942 | TRABECTEDIN |
| 330013158 | 330004834 | 1.59 | null | Palliative (P) | 2015-09-23 | 2015-09-30 | Cisplatin + Doxorubicin | 01 | N | 330014044 | CISPLATIN + DOXORUBICIN |
| 330013159 | 330004854 | 1.62 | 84.3 | Neo-adjuvant (N) | 2017-04-19 | 2017-06-19 | Cisplatin + Doxorubicin | N | N | 330014295 | CAV |
| 330013160 | 330008739 | 1.7 | null | Palliative (P) | 2014-01-07 | 2014-04-29 | Cyclophosphamide + Dex + Rituximab | N | N | 330015927 | TEMOZOLOMIDE |
| 330013161 | 330008745 | 1.93 | 82.6 | Palliative (P) | 2017-04-24 | 2017-04-28 | CNS HGG Temozolomide maintenance | 2 | N | 330015996 | CAV |
| 330013162 | 330005051 | 1.63 | 102 | Disease modification (D) | null | 2017-11-01 | FLAG + Idarubicin | null | null | 330016238 | FLAG + IDARUBICIN |
| 330013163 | 330005111 | 0 | 23.5 | Palliative (P) | 2018-06-27 | 2018-07-11 | EW Rel rEECur Irinotecan/Temozolomide | N | N | 330016923 | IRINOTECAN + TEMOZOLOMIDE |
| 330013164 | 330005121 | 1.56 | 0 | Curative (C) | 2014-06-27 | 2014-08-26 | Methotrexate intrathecal | 02 | N | 330016972 | METHOTREXATE INTRATHECAL |
| 330013165 | 330005125 | 1.78 | 69.1 | Palliative (P) | 2018-07-17 | 2018-09-29 | Azacitidine | N | N | 330017013 | DA |
| 330013166 | 330013343 | 1.72 | 58.4 | Palliative (P) | 2013-12-16 | 2014-03-19 | Azacitidine | N | N | 330017086 | TEMOZOLOMIDE |
| 330013168 | 330005204 | 1.87 | 23.7 | Curative (C) | 2017-06-02 | 2017-09-11 | Cisplatin + Doxorubicin | null | N | 330017807 | TEMOZOLOMIDE |
| 330013169 | 330005212 | 1.65 | 87.6 | Curative (C) | 2018-03-05 | 2018-03-06 | EW EuroEwing 99 : VActI | N | Y | 330017874 | EURO-EWING |
| 330013170 | 330008848 | 1.55 | 64.9 | Palliative (P) | 2017-08-03 | 2017-08-13 | Liposomal Doxorubicin (Caelyx) | N | N | 330018009 | LIPOSOMAL DOXORUBICIN |
| 330013171 | 330008874 | 1.63 | 46.4 | Disease modification (D) | null | 2018-03-16 | IMATINIB | Y | N | 330018777 | MITOTANE |
| 330013172 | 330005294 | null | null | Neo-adjuvant (N) | 2018-10-31 | 2018-10-31 | Cetuximab +Cisplatin + FU (Cycle 1) | N | N | 330018990 | UKALL XII |
| 330013173 | 330005299 | null | 59.4 | Curative (C) | 2019-03-11 | 2019-04-19 | GEMCITABINE | Y | N | 330019079 | CLOFARABINE + CYTSARABINE + IDARUBICIN |
| 330013175 | 330005367 | null | 62 | Palliative (P) | 2014-12-29 | 2015-12-11 | Carboplatin + Pemetrexed | null | null | 330019784 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330013176 | 330005378 | 1.72 | 109.2 | Curative (C) | 2014-09-23 | 2015-01-30 | AML17 TRIAL | N | N | 330019906 | MITOTANE |
| 330013177 | 330011907 | 0 | 75.7 | null | 2015-08-26 | 2015-08-26 | Mitotane 5.5 - 10g | Y | null | 330020236 | EMA/CO |
| 330013178 | 330005443 | 1.8 | 72 | Curative (C) | null | 2018-11-28 | DHAP | null | N | 330020433 | IFOSFAMIDE |
| 330013179 | 330010891 | 1.93 | 57.5 | Curative (C) | 2014-10-05 | 2015-04-04 | CNS LGG Irinotecan & Bevacizumab | Y | null | 330021093 | MERCAPTOPURINE |
| 330013181 | 330010894 | 1.72 | 80 | null | 2017-11-19 | 2018-01-14 | UKALL14- Ph 2 Induction | null | N | 330021120 | POMB/ACE |
| 330013182 | 330009044 | 1.78 | 54.3 | Palliative (P) | 2015-06-17 | 2016-01-03 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | N | N | 330021428 | GEMCITABINE + OXALIPLATIN |
| 330013183 | 330005594 | 1.8 | 52.4 | Curative (C) | 2014-04-01 | 2014-12-07 | Cyclophosphamide + Vincristine | 02 | N | 330021602 | CETUXIMAB + CISPLATIN + FU |
| 330013184 | 330005598 | 1.6 | 70.6 | Curative (C) | 2017-02-13 | 2017-02-22 | Triple / Double Intrathecal Therapy | 02 | N | 330021653 | IPILIMUMAB |
| 330013185 | 330005615 | 1.79 | 123.3 | Palliative (P) | null | 2015-01-21 | CAPECITABINE + VINORELBINE | N | N | 330021734 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330013186 | 330005644 | 0 | null | Curative (C) | 2018-03-11 | 2018-04-01 | EMA/CO | N | N | 330022242 | GEMCITABINE |
| 330013187 | 330005690 | 1.69 | 62.8 | Palliative (P) | 2017-01-18 | 2017-09-04 | STREPTOZOCIN | 02 | N | 330022926 | VINCRISTINE |
| 330013189 | 330005726 | 0 | null | Palliative (P) | 2019-06-26 | 2019-07-05 | FLUDARABINE | N | N | 330023279 | VIP |
| 330013190 | 330005744 | 1.47 | null | Curative (C) | 2019-04-13 | 2019-07-08 | Nintedanib | 1 | null | 330023355 | KESTREL TRIAL |
| 330013191 | 330005826 | 1.83 | 87.1 | Palliative (P) | 2017-12-15 | 2018-01-08 | CAP | 2 | N | 330024003 | CISPLATIN + GEMCITABINE |
| 330013192 | 330005833 | 1.76 | 74 | Disease modification (D) | 2018-08-02 | 2018-08-02 | Alemtuzumab + Cyclophos TBI Allo | 2 | N | 330024076 | TOPOTECAN |
| 330013194 | 330005911 | 1.85 | 71.2 | Curative (C) | 2015-08-27 | 2015-08-30 | AML 19 TRIAL | 02 | N | 330024541 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330013195 | 330005935 | 1.65 | 59 | Curative (C) | 2016-04-05 | 2016-09-17 | BUSULFAN + MELPHALAN | N | N | 330024769 | RUXOLITINIB |
| 330013196 | 330005958 | 1.8 | 17.6 | Palliative (P) | 2016-05-22 | 2016-05-26 | MERCAPTOPURINE + METHOTREXATE | 02 | N | 330024888 | UKALL 2011 |
| 330013197 | 330005981 | 1.7 | 61.7 | Curative (C) | 2020-01-27 | 2020-02-10 | CYCLOPHOSPHAMIDE + FLUDARABINE | 02 | N | 330025052 | HYDROXYCARBAMIDE |
| 330013198 | 330005987 | 1.6 | 53 | Palliative (P) | 2017-10-06 | 2017-10-07 | Carboplatin + Cetux + FU (>Cycle 2) | N | N | 330000507 | SUNITINIB |
| 330013199 | 330011044 | 1.79 | 77.25 | null | 2015-11-30 | 2015-12-10 | DE-ESCALATE TRIAL | 02 | null | 330004663 | CISPLATIN + DOXORUBICIN + METHOTREXATE |
| 330013200 | 330006023 | 1.82 | 19.7 | Palliative (P) | 2016-04-04 | 2016-04-04 | Cisplatin + Fluorouracil + RT 5day | N | N | 330006361 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE |
| 330013201 | 330006035 | 0 | 49 | Palliative (P) | 2018-06-18 | 2018-06-22 | CYCLOPHOSPHAMIDE | 02 | N | 330007632 | CAPECITABINE + CISPLATIN |
| 330013202 | 330006102 | 1.76 | 10.4 | Palliative (P) | null | 2015-05-17 | EMA | null | null | 330016564 | CAP |
| 330013203 | 330009332 | null | 78.8 | Palliative (P) | 2018-08-21 | 2018-08-26 | Alemtuzumab cond (RI ALLO CAMP100) | 02 | N | 330020339 | CAPECITABINE |
| 330013204 | 330006144 | 1.72 | 49 | Disease modification (D) | 2017-03-18 | 2017-07-04 | INTERFERON | N | N | 330024623 | VINCRISTINE |
| 330013205 | 330006156 | 1.58 | 86.7 | Palliative (P) | 2017-03-18 | 2017-09-01 | AML 19 TRIAL | N | N | 330007206 | CYTARABINE |
| 330013206 | 330002938 | 0 | 42.1 | Curative (C) | 2014-10-15 | 2014-10-18 | null | N | N | 330000050 | NOT MATCHED |
| 330013207 | 330002963 | null | 16.6 | Curative (C) | 2019-04-18 | 2019-04-19 | NB HRNBL-1 COJEC Ind COURSE C | null | null | 330000144 | NOT MATCHED |